Dr. Mahajan’s lab provides an immersive, intensive training environment for students and fellows to discover the molecular mechanisms that cause blindness and develop therapies to prevent vision loss. Highly collaborative research teams are made up of scientists, surgeons, and engineers from around the world, interacting on a daily basis and using advanced scientific methods.
Young Joo joined the lab in 2019. He received his bachelor’s degree in systems biology from the Yonsei University, Republic of Korea, in 2013 and completed his Ph.D. in biochemistry at the University of Iowa in 2019. Young Joo’s research interests are proteomics, structural biology, high-throughput screening, and protein-protein interaction engineering. He is currently working on structural biology of eye disease proteins.
Dylan joined the lab in 2019. He received his bachelor’s degree in chemistry from SUNY Geneseo in 2014 and completed his Ph.D. in chemistry at the University of Rochester. Dylan’s research interests include complex molecular synthesis and structure guided design of biologically relevant targets. He is currently working on the development and optimization of inhibitors for targets associated with eye disease.
Ahmad joined the lab in 2019. He graduated from Damascus Medical School, Syria. He then completed a research fellowship at Massachusetts Eye and Ear Institute, followed by a PhD in experiment pathology from Boston University School of Medicine. Ahmad also holds a master’s degree in public health from Northeastern University. Ahmad is working with data scientists in lab to identify molecular pathways in human retinal and inflammatory eye disease.
Jong joined the lab in 2018. He completed his undergraduate degree at the University of Toronto and medical school at Duke University. He completed a genetics fellowship as a Howard Hughes medical research fellow at Harvard’s Boston Children's Hospital. His research interests are in molecular genetics, uveitis, and retina. In the Mahajan Lab Jong uses human tissues to explore novel mechanisms and treatments for retinal inflammation.